Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;12(9):505-529.
doi: 10.4236/jct.2021.129044. Epub 2021 Sep 29.

Using Novel Statistical Techniques to Accurately Determine the Predictive Dose Range in a Study of Overall Survival after Definitive Radiotherapy for Stage III Non-Small Cell Lung Cancer in Association with Heart Dose

Joshua R Niska  1 , Jiuyun Hu  2 , Jing Li  3 , Michael G Herman  4 , Cameron S Thorpe  5 , Steven E Schild  5 , Mirek Fatyga  5
Affiliations

Using Novel Statistical Techniques to Accurately Determine the Predictive Dose Range in a Study of Overall Survival after Definitive Radiotherapy for Stage III Non-Small Cell Lung Cancer in Association with Heart Dose

Joshua R Niska et al. J Cancer Ther. 2021 Sep.

Abstract

Purpose: Recent studies of radiotherapy (RT) for stage III non-small-cell lung cancer (NSCLC) have associated high dose to the heart with cardiac toxicity and decreased overall survival (OS). We used advanced statistical techniques to account for correlations between dosimetric variables and more accurately determine the range of heart doses which are associated with reduced OS in patients receiving RT for stage III NSCLC.

Methods: From 2006 to 2013, 119 patients with stage III NSCLC received definitive RT at our institution. OS data was obtained from institutional tumor registry. We used multivariate Cox model to determine patient specific covariates predictive for reduced overall survival. We examined age, prescription dose, mean lung dose, lung V20, RT technique, stage, chemotherapy, tumor laterality, tumor volume, and tumor site as candidate covariates. We subsequently used novel statistical techniques within multivariate Cox model to systematically search the whole heart dose-volume histogram (DVH) for dose parameters associated with OS.

Results: Patients were followed until death or 2.5 to 81.2 months (median 30.4 months) in those alive at last follow up. On multivariate analysis of whole heart DVH, the dose of 51 Gy was identified as a threshold dose above which the dose volume relationship becomes predictive for OS. We identified V55Gy (percentage of the whole heart volume receiving at least 55 Gy) as the best single DVH index which can be used to set treatment optimization constraints (Hazard Ratio = 1.044 per 1% increase in heart volume exposed to at least 55 Gy, P = 0.03). Additional characteristics correlated with OS on multivariate analysis were age, stage (IIIA/IIIB), and administration of chemotherapy.

Conclusion: Doses above 51 Gy, applied to small volumes of the heart, are associated with worse OS in stage III NSCLC patients treated with definitive RT. Higher stage, older age and lack of chemotherapy were also associated with reduced OS.

Keywords: Cardiac Toxicity; Lung Cancer; Lung Radiation Therapy; Non-Small Cell Lung Cancer; Radiation Toxicity.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest Dr. Schild reports writing and editing for UpToDate. No conflicts exist for remaining authors.

References

    1. Lancellotti P, Nkomo VT, Badano LP, Bergler-Klein J, Bogaert J, Davin L, et al. (2013) Expert Consensus for Multi-Modality Imaging Evaluation of Cardiovascular Complications of Radiotherapy in Adults: A Report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. European Heart Journal: Cardiovascular Imaging, 14, 721–740. 10.1093/ehjci/jet123 - DOI - PubMed
    1. Dess RT, Sun Y, Matuszak MM, Sun G, Soni PD, Bazzi L, et al. (2017) Cardiac Events after Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 35, 1395–1402. 10.1200/JCO.2016.71.6142 - DOI - PMC - PubMed
    1. Wang K, Eblan MJ, Deal AM, Lipner M, Zagar TM, Wang Y, et al. (2017) Cardiac Toxicity after Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy. Journal of Clinical Oncology, 35, 1387–1394. 10.1200/JCO.2016.70.0229 - DOI - PMC - PubMed
    1. Xue J, Han C, Jackson A, Hu C, Yao H, Wang W, et al. (2019) Doses of Radiation to the Pericardium, Instead of Heart, are Significant for Survival in Patients with Non-Small Cell Lung Cancer. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 133, 213–219. 10.1016/J.radonc.2018.10.029 - DOI - PMC - PubMed
    1. Wang K, Pearlstein KA, Patchett ND, Deal AM, Mavroidis P, Jensen BC, et al. (2017) Heart Dosimetric Analysis of Three Types of Cardiac Toxicity in Patients Treated on Dose-Escalation Trials for Stage III Non-Small-Cell Lung Cancer. Radiotherapy and Oncology, 125, 293–300. 10.1016/j.radonc.2017.10.001 - DOI - PMC - PubMed

LinkOut - more resources